The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
In the latest session, Apogee Therapeutics Inc (NASDAQ: APGE) closed at $39.24 down -17.32% from its previous closing price of $47.46. In other words, the price has decreased by -$17.32 from its previous closing price. On the day, 6.0 million shares were traded. APGE stock price reached its highest trading level at $47.355 during the session, while it also had its lowest trading level at $38.0725.
Ratios:
For a deeper understanding of Apogee Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 15.82 and its Current Ratio is at 15.82. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BTIG Research on July 07, 2025, Reiterated its Buy rating but revised its target price to $115 from $100 previously.
On March 13, 2025, Citigroup started tracking the stock assigning a Buy rating and target price of $95.
On November 25, 2024, Canaccord Genuity started tracking the stock assigning a Buy rating and target price of $89.Canaccord Genuity initiated its Buy rating on November 25, 2024, with a $89 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jul 02 ’25 when Dambkowski Carl sold 10,090 shares for $45.09 per share. The transaction valued at 454,954 led to the insider holds 238,998 shares of the business.
CARL DAMBKOWSKI bought 22,345 shares of APGE for $988,990 on Jul 02 ’25. On Jun 04 ’25, another insider, Dambkowski Carl, who serves as the Chief Medical Officer of the company, sold 2,725 shares for $36.96 each. As a result, the insider received 100,716 and left with 241,723 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, APGE now has a Market Capitalization of 2288190464 and an Enterprise Value of 2033445504.
Stock Price History:
The Beta on a monthly basis for APGE is 1.48, which has changed by -0.021934211 over the last 52 weeks, in comparison to a change of 0.11708844 over the same period for the S&P500. Over the past 52 weeks, APGE has reached a high of $63.50, while it has fallen to a 52-week low of $26.20. The 50-Day Moving Average of the stock is -2.01%, while the 200-Day Moving Average is calculated to be -9.62%.
Shares Statistics:
For the past three months, APGE has traded an average of 746.57K shares per day and 1395900 over the past ten days. A total of 46.04M shares are outstanding, with a floating share count of 37.32M. Insiders hold about 37.32% of the company’s shares, while institutions hold 88.24% stake in the company. Shares short for APGE as of 1749772800 were 9175746 with a Short Ratio of 12.29, compared to 1747267200 on 10209991. Therefore, it implies a Short% of Shares Outstanding of 9175746 and a Short% of Float of 33.5.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Current recommendations for the stock of the company come from 5.0 analysts. The consensus estimate for the next quarter is -$1.09, with high estimates of -$0.89 and low estimates of -$1.32.
Analysts are recommending an EPS of between -$3.55 and -$4.94 for the fiscal current year, implying an average EPS of -$4.3. EPS for the following year is -$4.86, with 5.0 analysts recommending between -$3.83 and -$6.32.
